These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25836939)

  • 1. Second-line therapies in metastatic urothelial carcinoma.
    Narayanan S; Harshman LC; Srinivas S
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):341-59, x. PubMed ID: 25836939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.
    Sonpavde G; Pond GR; Rosenberg JE; Bajorin DF; Regazzi AM; Choueiri TK; Qu AQ; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Fougeray R; Dreicer R; Chen YH; Wong YN; Sridhar SS; Ko YJ; Milowsky MI; Galsky MD; Bellmunt J
    Clin Genitourin Cancer; 2015 Apr; 13(2):185-92. PubMed ID: 25458370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and management of upper tract urothelial carcinoma.
    Lucca I; Leow JJ; Shariat SF; Chang SL
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):271-88, ix. PubMed ID: 25836934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical consolidation of initially unresectable urothelial carcinoma: an incremental opportunity to cure.
    Siefker-Radtke AO
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1701-3. PubMed ID: 19954279
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design.
    Pond GR; Bellmunt J; Rosenberg JE; Bajorin DF; Regazzi AM; Choueiri TK; Qu AQ; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Fougeray R; Wong YN; Sridhar SS; Ko YJ; Milowsky MI; Galsky MD; Sonpavde G
    Clin Genitourin Cancer; 2015 Feb; 13(1):71-9. PubMed ID: 24993933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Targeted Therapies in Management of Metastatic Urothelial Cancer in the Era of Immunotherapy.
    Grivas P; Yu EY
    Curr Treat Options Oncol; 2019 Jun; 20(8):67. PubMed ID: 31254108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy for systemic urothelial cancer recurrence].
    Lehmann J; Stöckle M
    Urologe A; 2005 Apr; 44(4):369-74. PubMed ID: 15754166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving Treatment of Advanced Urothelial Cancer.
    Sridhar SS
    J Oncol Pract; 2017 May; 13(5):309-315. PubMed ID: 28489981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. INHBA overexpression indicates poor prognosis in urothelial carcinoma of urinary bladder and upper tract.
    Lee HY; Li CC; Huang CN; Li WM; Yeh HC; Ke HL; Yang KF; Liang PI; Li CF; Wu WJ
    J Surg Oncol; 2015 Mar; 111(4):414-22. PubMed ID: 25488476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.
    Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Pond G; Godbold J; Oh WK; Bamias A
    Urol Oncol; 2014 Jan; 32(1):48.e1-8. PubMed ID: 24055428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
    Pond GR; Bellmunt J; Fougeray R; Choueiri TK; Qu AQ; Niegisch G; Albers P; Di Lorenzo G; Salhi Y; Galsky MD; Agarwal N; Necchi A; Sonpavde G
    Clin Genitourin Cancer; 2013 Dec; 11(4):495-500. PubMed ID: 23800847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of gender on outcomes in patients with metastatic urothelial carcinoma.
    Haines L; Bamias A; Krege S; Lin CC; Hahn N; Ecke TH; Moshier E; Sonpavde G; Godbold J; Oh WK; Galsky MD
    Clin Genitourin Cancer; 2013 Sep; 11(3):346-52. PubMed ID: 23673281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditional Survival in de novo Metastatic Urothelial Carcinoma.
    Pal SK; Lin YI; Yuh B; DeWalt K; Kazarian A; Vogelzang N; Nelson RA
    PLoS One; 2015; 10(8):e0136622. PubMed ID: 26308952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature.
    Lughezzani G; Burger M; Margulis V; Matin SF; Novara G; Roupret M; Shariat SF; Wood CG; Zigeuner R
    Eur Urol; 2012 Jul; 62(1):100-14. PubMed ID: 22381168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations.
    Dietrich B; Siefker-Radtke AO; Srinivas S; Yu EY
    Am Soc Clin Oncol Educ Book; 2018 May; 38():342-353. PubMed ID: 30231356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chemotherapy indications in the treatment of metastases from urological malignancies].
    Théodore C
    Prog Urol; 2008 Nov; 18 Suppl 7():S219-22. PubMed ID: 19070795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches.
    Grivas PD; Melas M; Papavassiliou AG
    Semin Cancer Biol; 2015 Dec; 35():125-32. PubMed ID: 26304731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Options in metastatic urothelial cancer after first-line therapy.
    Alimohamed NS; Sridhar SS
    Curr Opin Support Palliat Care; 2015 Sep; 9(3):255-60. PubMed ID: 26262830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapies in the treatment of urothelial cancers.
    Aragon-Ching JB; Trump DL
    Urol Oncol; 2017 Jul; 35(7):465-472. PubMed ID: 28366271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upper tract urothelial carcinoma: special considerations.
    Hutchinson R; Haddad A; Sagalowsky A; Margulis V
    Clin Adv Hematol Oncol; 2016 Feb; 14(2):101-9. PubMed ID: 27057809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.